Apotea’s initial public offering on the Stockholm Stock Exchange today was overall successful. Some might consider the IPO pop from the listing price of 58 SEK to trading above 80 SEK (ca +40 %) to be a failure in pricing, but as the entire offering was secondary shares sold by old shareholders there are pro’s and con’s.
Old shareholders could sell a significant part of their holdings and get cash today (which otherwise can take between six months and two years).
The company got a mix of new shareholders, some large, well-known shareholders and 90,000 smaller ones. And everyone of them are happy (at least today).
Given the low volume of IPOs recently, leaving some money on the table and rather being safe than sorry might have been an ok trade-off for Apotea, but it was definitely a win for the companies planning to go public in 2025 as it helped to “open the IPO window”.
